Pfizer Canada and BioNTech said September 17 that Health Canada authorized the XFG variant-adapted COMIRNATY vaccine for people aged 6 months and older for the 2026-2027 season. The partners said the decision rests on prior clinical, non-clinical, and real-world evidence, and Pfizer Canada said it has enough inventory for federal and provincial contracts, with distribution in the coming days and weeks. The Canadian clearance covers a broader age group than the August 27 FDA approval, which applied to adults 65 and older and higher-risk people ages 5 to 64.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- BioNTech reports Q3 revenue of EUR 1.29 billionTuesday, November 3, 2026
- BioNTech reports first pumitamig data in second-line lung cancerTuesday, October 27, 2026
- BioNTech says a breast-cancer trial met a modest PFS goalTuesday, October 27, 2026
- BioNTech says BNT113 missed its progression-free survival goalThursday, October 15, 2026
